Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.60 |
| ▸ | MLYCD | O95822 | 14/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945331 | 0.81 | MLYCD (0.78) | NR1H2NR1H3MLYCDRORC | |
| SCHEMBL2945327 | 0.76 | MLYCD (0.75) | NR1H2NR1H3MLYCD | |
| SCHEMBL2942014 | 0.76 | MLYCD (0.70) | NR1H2NR1H3MLYCD | |
| SCHEMBL4720669 | 0.75 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL6843869 | 0.75 | MLYCD (1.00) | MLYCD | |
| SCHEMBL2942439 | 0.74 | MLYCD (1.00) | NR1H2NR1H3MLYCD | |
| SCHEMBL25687491 | 0.74 | MLYCD (0.56) | NR1H2NR1H3MLYCDRORC | |
| Hydrochloric Acid SCHEMBL4420053 | 0.73 | MLYCD (0.63) | NR1H2NR1H3MLYCD | |
| SCHEMBL2944310 | 0.73 | MLYCD (0.79) | NR1H2NR1H3MLYCDRORC | |
| SCHEMBL25687502 | 0.73 | MLYCD (0.56) | MLYCDRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4503232-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| JP-4503896-B2 | — | — | 2010-07-14 | — | — | JP | claimed |
| JP-2004521113-A | — | — | 2004-07-15 | — | — | JP | claimed |
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
| EP-1353662-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-22 | — | — | EP | claimed |
| JP-2003502309-A | — | — | 2003-01-21 | — | — | JP | claimed |
| WO-2002058690-A2 | METHODS FOR THE TREATMENT OF DISEASES USING MALONYL-COA DECARBOX YLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | claimed |
| EP-1194404-A1 | INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000076961-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-21 | — | — | WO | claimed |
| CN-109562048-A | For promoting the composition and method of skin health | 加州大学评议会 | 2019-04-02 | — | — | CN | disclosed |
| CN-107406378-A | Sulfurized alkyl compounds and pyridine trans sulfonamide compounds for HBV treatment | 诺维拉治疗公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-102186497-B | Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs | UAB RESEARCH FOUNDATION | 2015-02-25 | — | — | CN | disclosed |
| CN-102186497-A | Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs | UAB RESEARCH FOUNDATION | 2011-09-14 | — | — | CN | disclosed |
| EP-1786815-A4 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC (CA) | 2009-03-18 | — | — | EP | disclosed |
| WO-1995015395-A2 | NUCLEOSIDE ANALOGUE METHOD | AMERSHAM INTERNATIONAL PLC (GB) | 1995-06-08 | — | — | WO | disclosed |
| EP-0594677-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | NeXstar Pharmaceuticals, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993000910-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| EP-0394346-A4 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | US HEALTH (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0394346-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1990-10-31 | — | — | EP | disclosed |
| WO-1989006235-A1 | PYRIMIDINE AND PURINE 1,2-BUTADIENE-4-OLS AS ANTI-RETROVIRAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | NR1H2 1139/4885NR1H3 1227/4885MLYCD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.